ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0266

Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression

Judith Heutz1, Cleo Rogier2, Ellis Niemantsverdriet3, Susan van den Eeden4, Pascal de Jong5, Annemieke Geluk6 and Annette van der Helm-van Mil7, 1Erasmus Medical Center, Rotterdam, Netherlands, 2Erasmus MC, Rotterdam, Netherlands, 3LUMC, Leiden, Netherlands, 4Leiden University Medical Center (LUMC), Leiden, Netherlands, 5ErasmusMC, Hendrik Ido Ambacht, Netherlands, 6Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, 7Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2022

Keywords: chemokines, cytokines, Gene Expression, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Autoantibody responses rise years before onset of inflammatory arthritis (IA) and are stable during transitioning from clinically suspect arthralgia (CSA) to IA (1). Cytokine and chemokine levels can also rise years before IA-onset, whilst CSA generally develops 6-12 months prior to IA-onset (2). Since the course of cytokines/chemokines in CSA is unknown, we studied the course of cytokine and chemokine gene expression in CSA-patients during progression to IA, and in CSA-patients who ultimately did not develop IA. Differential expressed genes between ACPA-positive and ACPA-negative CSA patients who developed IA were explored.

Methods: Whole blood RNA expression of 37 candidate inflammatory cytokines and chemokines was determined by dual-color reverse-transcription multiplex ligation-dependent probe amplification (dcRT-MLPA), in paired samples of CSA-patients at CSA-onset and either at IA-development or after 24-months without progression. ACPA-positive and ACPA-negative CSA-patients developing IA were compared at CSA-onset and during progression. GEE-models tested changes over time. A false discovery rate approach was applied to correct for multiple testing.

Results: In CSA-patients who progressed to IA, gene expression of none of the cytokines and chemokines significantly changed between CSA-onset and IA-development (Figure 1). In CSA-patients who did not progress to IA, G-CSF expression decreased (p=0.001) and CCR6 and TNIP expression increased (p< 0.001 and p=0.002, respectively) in 2-years (Figure 2). Gene expression levels in ACPA-positive and ACPA-negative CSA-patients who developed IA were similar.

Conclusion: Whole blood cytokine and chemokine gene expression did not change significantly over time from CSA to IA-development. This suggests that changes in systemic expression occurred preceding CSA-onset and may not relate to the final hit of developing chronic disease. Observed changes in CSA patients not developing IA can provide clues for processes related to resolution.

References
1. Wouters F et al. Ann Rheum Dis. 2020;80(4):540-2
2. Sokolove J et al. PLos One 2012;7(5):e35296

Supporting image 1

Figure 1. Modelled course of gene expression of 37 cytokines and chemokines in CSA patients who progressed to arthritis. Cytokines and chemokines were measured at baseline and at time of IA development. CSA, clinical suspect arthralgia; IA, inflammatory arthritis

Supporting image 2

Figure 2. Modelled course of gene expression of G-CSF, CCR6 and TNIP1 in CSA patients who did not progress to arthritis and patients that did progress to arthritis. Cytokines and chemokines were measured at baseline and after 2 years. CSA, clinical suspect arthralgia


Disclosures: J. Heutz, None; C. Rogier, None; E. Niemantsverdriet, None; S. van den Eeden, None; P. de Jong, None; A. Geluk, None; A. van der Helm-van Mil, None.

To cite this abstract in AMA style:

Heutz J, Rogier C, Niemantsverdriet E, van den Eeden S, de Jong P, Geluk A, van der Helm-van Mil A. Expression of Cytokine and Chemokine Genes in Patients with Clinically Suspect Arthralgia; A Longitudinal Study During Progression to Inflammatory Arthritis or Non-Progression [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/expression-of-cytokine-and-chemokine-genes-in-patients-with-clinically-suspect-arthralgia-a-longitudinal-study-during-progression-to-inflammatory-arthritis-or-non-progression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-of-cytokine-and-chemokine-genes-in-patients-with-clinically-suspect-arthralgia-a-longitudinal-study-during-progression-to-inflammatory-arthritis-or-non-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology